22. In establishing requirements for pharmacists to engage in collaborative practice as provided in paragraph (4) of subsection a. of section 9 of this act, the board shall include in these requirements, but not be limited to, provisions that any written protocol between a physician and pharmacist:

a. is agreed to by both the physician and the pharmacist with the consent of the patient;

b. identifies, by name and title, each physician and each pharmacist who is permitted to participate in a patient’s collaborative drug therapy management;

c. specifies the functions and responsibilities the pharmacist will be performing;

d. is available at the practice sites of the pharmacist and physician and made available at each site to the patient;

e. is initiated and utilized at the sole discretion of the physician for a specific patient;

f. may be terminated at any time by either party by written documentation;

g. establishes when physician notification is required, the physician chart update interval, and an appropriate time frame within which the pharmacist must notify the physician of any change in dose, duration or frequency of medication prescribed;

h. remains in effect for a period not to exceed two years upon the conclusion of which, or sooner, the parties shall review the protocol and make a determination as to its renewal, modification or termination; and

i. establish the means by which the patient will be advised of the right to elect to participate in and withdraw from the collaborative drug therapy management.

L.2003,c.280,s.22.